Cresanto Global Limited
Incorporated in 1994, Raymed Labs Ltd is in
the business of providing ophthalmological products[1]
- Market Cap ₹ 1.99 Cr.
- Current Price ₹ 4.65
- High / Low ₹ 4.65 / 3.48
- Stock P/E
- Book Value ₹ -7.07
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 32.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | |
| 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 | 0.07 | 0.08 | 0.19 | 0.10 | 0.60 | 0.34 | |
| Operating Profit | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 | -0.06 | -0.07 | -0.08 | -0.19 | -0.10 | -0.60 | -0.29 |
| OPM % | -580.00% | |||||||||||
| 0.02 | 0.00 | -0.01 | -0.02 | -0.02 | 0.01 | 0.01 | 0.00 | 0.02 | 0.00 | 0.53 | 0.02 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.16 |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.02 | -0.04 | -0.05 | -0.06 | -0.06 | -0.06 | -0.07 | -0.09 | -0.18 | -0.10 | -0.18 | -0.43 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| -0.02 | -0.04 | -0.05 | -0.06 | -0.05 | -0.06 | -0.07 | -0.08 | -0.17 | -0.10 | -0.18 | -0.43 | |
| EPS in Rs | -0.05 | -0.09 | -0.12 | -0.14 | -0.12 | -0.14 | -0.16 | -0.19 | -0.40 | -0.23 | -0.42 | -1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 38% |
| 3 Years: | 32% |
| 1 Year: | 34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 |
| Reserves | -6.00 | -6.04 | -6.09 | -6.15 | -6.20 | -6.26 | -6.33 | -6.41 | -6.58 | -6.68 | -6.86 | -7.29 |
| 2.00 | 1.99 | 2.03 | 2.04 | 2.05 | 2.07 | 2.21 | 0.05 | 0.00 | 2.43 | 2.37 | 2.81 | |
| 0.04 | 0.06 | 0.07 | 0.11 | 0.14 | 0.18 | 0.10 | 2.33 | 2.47 | 0.13 | 0.25 | 0.22 | |
| Total Liabilities | 0.31 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.24 | 0.16 | 0.15 | 0.03 | 0.01 |
| 0.20 | 0.19 | 0.19 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.15 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.11 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.01 | 0.00 | 0.03 | 0.01 | |
| Total Assets | 0.31 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.24 | 0.16 | 0.15 | 0.03 | 0.01 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.21 | -0.16 | -0.06 | -0.47 | -0.43 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.21 | 0.16 | 0.06 | 0.59 | 0.44 | |
| 0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.11 | 0.00 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Free Cash Flow | -0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.21 | -0.16 | -0.06 | 0.18 | -0.43 |
| CFO/OP | 75% | -33% | 0% | 0% | 0% | 0% | 0% | 2,762% | 84% | 60% | 78% | 148% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | |||||||||||
| Inventory Days | 0.00 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | |||||||||||
| Working Capital Days | -1,606.00 | |||||||||||
| ROCE % | -7.84% | -8.16% | -13.95% | -16.22% | -21.43% | -60.00% | -60.87% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Employee Count Number |
|
|||||||
Extracted by Screener AI
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 4 Jun
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 3 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Please find the attached Newspaper Notice for Publication of Q4 and Year ended 31 March, 2026 Results
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Annual Secretarial Compliance Report not applicable for FY2026; paid-up capital and net worth below thresholds.
-
Results For The Q4 And Financial Year Ended 31 March, 2026
28 May - Board approved audited FY26 results on 28 May 2026; auditors issued unmodified opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
RMIL manufactures formulations with advanced technologies focusing into Preservative free Ophthalmic dosage for Conjunctivitis and Glaucoma Patient care. It also manufactures other formulations which are converted from suspension to solution. Company has a range of over 80 products. It is a trademark owner of ophthalmic solution (eye drops), antioxidant capsules and tablets. RMIL is also into publication business.